Astellas Drops Suit Over Medicare Drug Price Negotiation Law
Astellas Pharma on Wednesday dropped its challenge to the new Medicare drug price negotiation program after none of its products were selected for negotiation by the U.S. Department of Health and...To view the full article, register now.
Already a subscriber? Click here to view full article